SmartCardia, a leading MedTech company, won Frost & Sullivan’s 2022 Global New Product Innovation Award for its revolutionary 7-Lead ECG patch for cardiology and remote patient monitoring. The company’s 7L patch enables real-time patient assessment through cloud-based Artificial Intelligence (AI) software, which provides smart and accurate analysis for long-term monitoring and cost savings.
SmartCardia is working towards transforming the healthcare sector with its cutting-edge data-driven technology that helps identify and prevent unforeseen cardiac events. Technology has enabled doctors to care for thousands of patients in hundreds of hospitals globally. SmartCardia provides its technology to more than 200+ hospitals. In India, the company is present in 15+ cities, and is planning to expand in over 80+ cities in the year 2023. SmartCardia will also increase its footprints in Tier 2 and Tier 3 cities to reach the rural population.
Dr. Srinivasan Murali, CEO, and Co-founder, SmartCardia, said, “We are delighted to receive Frost & Sullivan’s 2022 Global New Product Innovation Award. We started our journey with the aim of providing better healthcare to patients with the help of AI-enabled wearable devices. This award has reinforced our aspiration to be the leader in the cardiac care domain as an innovator of intelligent and highly personalized solutions.”
With a cloud-based solution, SmartCardia provides AI-based real-time actionable insights and alerts to diagnose critical conditions accurately. The company has pushed the boundaries of its vast experience and world-class capabilities to revolutionize cardiovascular health in India by offering clinical-quality data and scientific validation, bringing a unique perspective on remote patient monitoring.
Dr. Murali added “We strive to increase our global presence in different regions while bringing value to customers by providing robust, reliable, and innovative solutions and speeding up research and development efforts. We forayed into India a year back and excited to serve the US market in 2023. We are committed to innovating to meet the patient’s demands and anticipate future expectation”.
SmartCardia deploys clinically feasible and meaningful innovations to plan its product development through physician and patient feedback. Thus, the company ensures its offerings are in line with market demands.